165 related articles for article (PubMed ID: 34150374)
1. Triple-Negative Metaplastic Breast Carcinoma: Association of Epidermal Growth Factor Receptor Expression With Prognostic Parameters and Clinical Outcome.
Munawar S; Haider R; Ali SM; Yaqeen SR; Islam S; Asghar IA; Afzal A; Zia S; Irfan M; Hashmi AA
Cureus; 2021 May; 13(5):e15006. PubMed ID: 34150374
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer.
Hashmi AA; Naz S; Hashmi SK; Hussain ZF; Irfan M; Khan EY; Faridi N; Khan A; Edhi MM
BMC Clin Pathol; 2018; 18():9. PubMed ID: 30305801
[TBL] [Abstract][Full Text] [Related]
4. Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma.
Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
[TBL] [Abstract][Full Text] [Related]
5. Encapsulated Papillary Carcinoma of Breast: Clinicopathological Features and Prognostic Parameters.
Hashmi AA; Iftikhar SN; Munawar S; Shah A; Irfan M; Ali J
Cureus; 2020 Oct; 12(10):e11282. PubMed ID: 33274157
[TBL] [Abstract][Full Text] [Related]
6. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
7. Solid Papillary Carcinoma of Breast: Clinicopathologic Comparison With Conventional Ductal Carcinoma of Breast.
Hashmi AA; Iftikhar SN; Haider R; Haider R; Irfan M; Ali J
Cureus; 2020 Oct; 12(10):e11172. PubMed ID: 33262909
[TBL] [Abstract][Full Text] [Related]
8. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
9. Metaplastic breast carcinoma: a clinical analysis of 26 cases.
Jin X; Yu D; Guo C; Gong X; Li N; Zhao Y
Int J Clin Exp Pathol; 2018; 11(4):2112-2117. PubMed ID: 31938320
[TBL] [Abstract][Full Text] [Related]
10. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
11. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic carcinoma of the breast: clinicopathological features and immunohistochemical analysis.
Yilmaz KB; Pak I; Irkkan C; Ozaslan C; Atalay C
J BUON; 2011; 16(4):652-6. PubMed ID: 22331717
[TBL] [Abstract][Full Text] [Related]
13. Metaplastic breast carcinomas and their relationship with basal-like phenotype.
Cakir A; Gönül II; Uluoğlu O
Turk Patoloji Derg; 2012; 28(2):134-41. PubMed ID: 22627631
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center.
Zhang Y; Lv F; Yang Y; Qian X; Lang R; Fan Y; Liu F; Li Y; Li S; Shen B; Pringle GA; Zhang X; Fu L; Guo X
PLoS One; 2015; 10(6):e0131409. PubMed ID: 26115045
[TBL] [Abstract][Full Text] [Related]
15. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
16. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity.
Lim KH; Oh DY; Chie EK; Han W; Im SA; Kim TY; Park IA; Noh DY; Ha SW; Bang YJ
Jpn J Clin Oncol; 2010 Feb; 40(2):112-8. PubMed ID: 19887523
[TBL] [Abstract][Full Text] [Related]
17. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
18. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
19. Descriptive study of the histopathological subtypes and programmed death-ligand 1 in metaplastic breast carcinoma.
Stephen N; Jinkala S; Ch Toi P; Ganesh RN; Bheemanathi Hanuman S; Badhe BA; Gochhait D; Dubashi B
Breast J; 2020 Dec; 26(12):2371-2375. PubMed ID: 32959535
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas.
Changavi AA; Shashikala A; Ramji AS
J Lab Physicians; 2015; 7(2):79-83. PubMed ID: 26417156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
